Abstract:Rejection of solid organ transplant and graft versus host disease (GvHD) continue to be challenging in post transplantation management. The introduction of calcineurin inhibitors dramatically improved recipients' short-term prognosis. However, long-term clinical outlook remains poor, moreover, the lifelong dependency on these toxic drugs leads to chronic deterioration of graft function, in particular the renal function, infections and de-novo malignancies. These observations led investigators to identify alternative therapeutic options to promote long-term graft survival, which could be used concomitantly, but preferably, replace pharmacologic immunosuppression as standard of care. Adoptive T cell (ATC) therapy has evolved as one of the most promising approaches in regenerative medicine in the recent years. A range of cell types with disparate immunoregulatory and regenerative properties are actively being investigated as potential therapeutic agents for specific transplant rejection, autoimmunity or injury-related indications. A significant body of data from preclinical models pointed to efficacy of cellular therapies. Significantly, early clinical trial observations have confirmed safety and tolerability, and yielded promising data in support of efficacy of the cellular therapeutics. The first class of these therapeutic agents commonly referred to as advanced therapy medicinal products have been approved and are now available for clinical use. Specifically, clinical trials have supported the utility of CD4 + CD25+FOXP3+ regulatory T cells (Tregs) to minimize unwanted or overshooting immune responses and reduce the level of pharmacological immunosuppression in transplant recipients. Tregs are recognized as the principal orchestrators of maintaining peripheral tolerance, thereby blocking excessive immune responses and prevent autoimmunity. Here, we summarize rationale for the adoptive Treg therapy, challenges in manufacturing and clinical experiences with this novel living drug and outline future perspectives of its use in transplantation.

T Regulatory Cells As an Immunotherapy for Transplantation

T regulatory cells as an immunotherapy for transplantation.

Regulatory T Cell Therapy for the Induction of Clinical Organ Transplantation Tolerance

Impact of Regulatory T Cells on Innate Immune Cells in a Pre-Sensitized Heart Transplant Model

Regulatory T cells and transplantation tolerance.

Regulatory T Cells in Transplantation Tolerance

Regulating Regulatory T Cells to Achieve Transplant Tolerance.

CD4+CD25+ regulatory T cell therapy for the induction of donor-specific clinical transplantation tolerance.

Tregs in transplantation tolerance: role and therapeutic potential

Induced Regulatory T Cells as Immunotherapy in Allotransplantation and Autoimmunity: Challenges and Opportunities

Antigen Specific Regulatory T Cells in Kidney Transplantation and Other Tolerance Settings

Guiding regulatory T cells to the allograft

Therapy with regulatory T-cell infusion in autoimmune diseases and organ transplantation: A review of the strengths and limitations

Transfer of Regulatory T Cells Generated Ex Vivo Modifies Graft Rejection Through Induction of Tolerogenic CD4+CD25+ Cells in the Recipient

Antigen-Dependent Suppression of Alloresponses by Foxp3-Induced Regulatory T Cells in Transplantation

Clinical adoptive regulatory T Cell therapy: State of the art, challenges, and prospective

Role of CD8+ Regulatory T Cells in Organ Transplantation

Adoptive Transfer of Regulatory Immune Cells in Organ Transplantation

Role and mechanisms of CD4+CD25+ regulatory T cells in the induction and maintenance of transplantation tolerance.

In Vivo Environment Necessary to Support Transplanted Donor Mouse T Regulatory Cells

Regulatory T-Cell Counter-Regulation by Innate Immunity Is a Barrier to Transplantation Tolerance